Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy

[1]  D. Anaya,et al.  Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma , 2011, Cancer.

[2]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here? , 2011, Annals of Surgical Oncology.

[3]  Jeffrey E. Lee,et al.  Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation , 2010, Annals of Surgical Oncology.

[4]  C. Bassi,et al.  Resectable Pancreatic Cancer: Who Really Benefits From Resection? , 2009, Annals of Surgical Oncology.

[5]  M. Choti,et al.  Determining Pattern of Recurrence Following Pancreaticoduodenectomy and Adjuvant 5-Flurouracil-Based Chemoradiation Therapy: Effect of Number of Metastatic Lymph Nodes and Lymph Node Ratio , 2009, Journal of Gastrointestinal Surgery.

[6]  Sunil Krishnan,et al.  Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma , 2009, Annals of Surgical Oncology.

[7]  A. Stessin,et al.  Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. , 2008, International journal of radiation oncology, biology, physics.

[8]  Jeffrey E. Lee,et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Jeffrey E. Lee,et al.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. , 2008, Journal of the American College of Surgeons.

[11]  Laura H. Tang,et al.  Pancreatic Adenocarcinoma: The Actual 5-Year Survivors , 2008, Journal of Gastrointestinal Surgery.

[12]  J. Donohue,et al.  Long-Term Survival After Pancreatoduodenectomy for Pancreatic Adenocarcinoma: Is Cure Possible? , 2008, Annals of surgery.

[13]  Jennifer J. Gibson,et al.  Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. , 2008, Journal of the American College of Surgeons.

[14]  Douglas B. Evans,et al.  Tumor‐Node‐Metastasis Staging of Pancreatic Adenocarcinoma , 2008, CA: a cancer journal for clinicians.

[15]  Douglas B. Evans,et al.  Development of an Integrated Biospecimen Bank and Multidisciplinary Clinical Database For Pancreatic Cancer , 2008, Annals of Surgical Oncology.

[16]  Jeffrey E. Lee,et al.  Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? , 2007, Journal of the American College of Surgeons.

[17]  Bryan A. Whitson,et al.  Trends in the Treatment and Outcome of Pancreatic Cancer in the United States , 2007, Annals of Surgical Oncology.

[18]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.

[19]  K. Campbell,et al.  Resected periampullary adenocarcinoma: 5-year surVIVOrs and their 6 to 10-year follow-up , 2006 .

[20]  S. Gallinger,et al.  Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. , 2004, Journal of the American College of Surgeons.

[21]  Jeffrey E. Lee,et al.  Abstracts reprinted from Journal of Clinical Oncology , 2002, Annals of Surgical Oncology.

[22]  Douglas B. Evans,et al.  Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. , 2002, The oncologist.

[23]  Jeffrey E. Lee,et al.  Effect of Preoperative Biliary Decompression on Pancreaticoduodenectomy-Associated Morbidity in 300 Consecutive Patients , 2001, Annals of surgery.

[24]  B. Eisenberg,et al.  Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas , 2001, Journal of Gastrointestinal Surgery.

[25]  R. Wolff,et al.  Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Jeffrey E. Lee,et al.  Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Lu,et al.  Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. , 1997, AJR. American journal of roentgenology.

[28]  A. Piccoli,et al.  Recurrence after resection for ductal adenocarcinoma of the pancreas , 1997, World Journal of Surgery.

[29]  F. Ames,et al.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1992, Archives of surgery.

[30]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[31]  Jeffrey E. Lee,et al.  Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer , 2011, Journal of Gastrointestinal Surgery.

[32]  J. Drebin.  National Failure to Operate on Early Stage Pancreatic Cancer , 2008 .

[33]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.